INTRODUCTION
Based on literature sources Urothelial carcinomas (UCs) are the fourth most common tumors [1] . They can be located in the lower (bladder and urethra) or upper (pyelocaliceal cavities and ureter) urinary tract. UTUCs are uncommon and account for only 5-10 % of UCs [1, 2] , with an estimated annual incidence in Western countries klinikinės-praktinės apžvalgos of ~2 cases per 100,000 inhabitants. Pyelocaliceal tumors are about twice as common as ureteral tumors. Epithelial tumors of the kidney account for approximately 3 % of all solid neoplasms, with adenocarcinoma or renal cell carcinoma (RCC) representing almost 85 % [3] . Herein, we report a rare case of upper tract high malignancy urothelial carcinoma with atypical clinic which looks like an apostematous pyelonephritis. Upper tract urothelial carcinoma and RCC are two different types of malignancy that are distinguished on the basis of tissue type and location. Differentiation of these malignancies is challenging but necessary because the management strategies and standard of treatment differs. In terms of diagnosis, the most common symptom is visible or non-visible hematuria (70-80 %) [4] . Flank pain occurs in 20-40 % of cases, and a lumbar mass is present in 10-20 % [5, 6] . Systemic symptoms (including anorexia, weight loss, malaise, fatigue, fever, night sweats, or cough) associated with UTUC should prompt more rigorous metastatic evaluation [5, 6] . Computed tomography urography (CTU) has the highest diagnostic accuracy for high-risk patients [4] . The sensitivity of CTU for UTUC is 0.67-1.0 and the specificity is 0.93-0.99 [4] . Magnetic resonance urography (MRU) is indicated in patients who cannot undergo CTU, usually when radiation or iodinated contrast media are contraindicated [7] . Urinary cytology should be performed as part of a standard diagnostic work-up. A cystoscopy should be done to rule out concomitant bladder tumor. Upper tract urothelial carcinomas that invade the muscle wall usually have poor prognosis. The 5-year specific survival is < 50 % for pT2/pT3 and < 10 % for pT4 [8] [9] [10] . Radical nephroureterectomy must comply with oncological principles, which consist of preventing tumor seeding by avoiding entry into the urinary tract during resection [11] . In this article, we describe an unusual progressing case of renal pelvic UC with atypical clinic.
CASE REPORT
A 72 age women who has started suffering by fever 37,5-37,8 C o about three months ago. Since then she has lost 18 kg because of weak appetite. During all that time she has got a treatment with antibiotic at 5 times, but effect was extremely short and failed. She had the nonspecific symptom of fatigue since 3 month previously. Of all medical documents are known that patient was examined by pulmonologist, urologist, gynecologist, but acute surgical disease has not been established. At this time patient was hospitalized for fever of unknown origin, anemia of unknown origin and right side pain. No palpable mass was detected on the physical examination. The urine and blood analysis demonstrated bacterial urinary tract infection with hematuria. The ultrasound has shown that right kidney was diffuse abnormal and increased. The typical structure was gone. The surrounding tissue was infiltrated and looks like a apostematous pyelonephritis. The ultrasound has shown the urostasis and expanded ureter with inner mass. The right adrenal gland was abnormal also and the lymph nodes were enlarged in the inferior vena cava area and right iliac area. The aspirate biopsy monitored by ultrasound has shown invasive urothelial carcinoma of high malignant potential (Immunophenotype: PANCK/CK7/CD10/PAX8/ INI1/GATA3/p63(+); CK20/RCC(-); Uroplakin III/Carboanhidrasis IX(+/-); CD20/CD3/CD30(-)). The Computed tomography urography has shown the right renal mass with areas of necrosis and suspicious perirenal fat infiltration and invasion to the right adrenal gland. Some lymph nodes were enlarged in the aortocaval area. A diagnosis of invasive urothelial carcinoma (T3N1Mx) was made and a radical nephrectomy with lymphadenectomy was planned.
Under general anesthesia, the patient was placed in the supine position with the right side elevation. A midline abdominal incision and right Kocher incision was done to expose the right kidney. The right kidney artery was ligated. The right kidney vena was ligated also. After that and reconstruction was accomplished by use of no absorbable sutures. En Bloc resection of the right renal mass and regional lymphadenectomy were performed successfully.
DISCUSSION
This case of upper tract invasive urothelial carcinoma with unusual symptoms are unique and rare and for this reason these patient with upper tract urothelial invasive carcinoma was required to be investigated by professional team with different specialist. Upper tract urothelial carcinoma is an uncommon genitourinary malignancy that accounts for about 5 % of urothelial cancers and less than 10 % of renal tumors. Invasive urothelial carcinoma prognosis correlates with histological grade and stage [12, 13] . Advanced disease stages, such as aggressive invasion into renal parenchyma or perirenal fat carry a poor prognosis [14] . Less than 30 cases reported in the literature we could find the urothelial carcinoma with inferior vena cava thrombosis or similar overgrowth [15] . Urothelial carcinomas of the renal pelvis also more often appear to be of a higher stage than their urinary bladder counterparts [16] . In our case, the diagnose was determined by aspirating biopsy result and preoperative CTU. The Computed tomography urography has shown the right renal mass with areas of necrosis and suspicious perirenal fat infiltration and invasion to the right adrenal gland. Some lymph nodes were enlarged in the aortocaval area. From this finding, a standard radical nephrectomy and regional lymphadenectomy were performed. The prognosis of patients with an invasive urothelial carcinoma is poor compared with that of patients with RCC [17] . Upper tract urothelial carcinomas that invade the muscle wall usually have poor prognosis. The 5-year specific survival is < 50 % for pT2/pT3 and < 10 % for pT4 [10, 18, 19] . Risk stratification of upper tract urothelial carcinoma divided to low and high risk upper tract urothelial carcinoma and it's listed below [20] .
gnose was determined in advanced stage. In few article you can find the good response of neoadjuvant chemotherapy to downstaging, although survival data need to mature and longer follow-up is awaited [25] . After a comprehensive search of studies examining the role of chemotherapy for upper tract urothelial cancer, the pooled evidence shows that cisplatin-based adjuvant chemotherapy was beneficial for prolonging survival [26] . Chemotherapy followed by retroperitoneal LND for isolated retroperitoneal recurrence after nephroureterectomy for upper UTUC was feasible and safe treatment that may be potentially therapeutic in selected patients. The follow-up of upper tract urothelial carcinoma patients after initial treatment on Invasive tumor cases is Cystoscopy/urinary cytology at 3 months and then yearly and CT urography every 6 months over 2 years and then yearly.
RNU remains as the gold standard treatment for highrisk UTUC. However, relapse and metastasis are highly common in UTUC patients after RNU, affecting longterm survival. Perioperative treatments have been used to reduce relapse and prolong survival. However, the optimal perioperative therapy is still uncertain. AC adjuvant chemotherapy is the most widely used treatment in patients with cancer after undergoing surgery. Leow, J. J. et al. suggested the potential benefit in overall survival (OS) and disease-free survival (DFS) of cisplatin-based AC in UTUC [27] . A retrospective studies found that neo adjuvant chemotherapy may prolong the survival of patients compared with the matched cohort who underwent initial surgery, but additional trials are necessary to confirm the treatment's utility [28] . On the basis of Literature we found that both AC and NAC improve OS and DFS of UTUC patients after RNU [29] .
CONCLUSIONS
Urothelial carcinoma should be included in the differential diagnosis of all renal tumors and the most of apostematous pyelonephritis. Retrospectively assessing our patient has the most common symptoms of urinary tract infection and malignancy. It was non-visible hematuria, flank pain, chronic urinary tract infection, and also systemic symptoms (including anorexia, weight loss, malaise, fatigue, fever, and night sweats). The right diagnose we have determined by biopsy and CTU. In this case the team of urologist, vascular surgeon, anesthesiologist and diagnostic radiologist took care the patient heath, however prognosis are poor. Open RNU with bladder cuff excision is the standard for highrisk UTUC, regardless of tumor location and bladder cuff removal is imperative. On the basis in Literature we found that both AC and NAC improve OS and DFS of UTUC patients after RNU. * All of these factors need to be present ** Any of these factors need to be present MDCT = multidetector-row computed tomography; URS = ureterorenoscopy.
Talking about disease management UTUC with invasive to muscle layer must be treated radical. Open RNU with bladder cuff excision is the standard for high-risk UTUC, regardless of tumor location and bladder cuff removal is imperative [11] . Radical nephroureterectomy must comply with oncological principles, which consist of preventing tumor seeding by avoiding entry into the urinary tract during resection [11] . There are no benefits of RNU in metastatic disease, although it can be considered as palliative [11, 21] . Regardless aggressive radical nephrectomy, most patients with metastasis died within six months of initial diagnosis.
Systemic chemotherapy can be used as an adjuvant treatment for these patients, but the efficacy is unclear. Upper tract urothelial carcinomas are urothelial tumors; therefore, platinum-based chemotherapy is expected to have similar efficacy as in bladder cancer. However, there are currently insufficient data for recommendations. There are several platinum-based regimens [22] , but the risk of impaired postoperative function means that neoadjuvant chemotherapy is only optional. Not all patients can receive chemotherapy because of comorbidity and impaired renal function after radical surgery. Chemotherapy-related toxicity, particularly nephrotoxicity from platinum derivatives, may significantly reduce survival in patients with postoperative renal dysfunction [23, 24] . In our case we have bad prognosis. The control all body CT showed many metastases in liver, lung and bones. All symptoms of this patient before surgery was unique and similar to urinary tract infection. The dia-
